- KR₩45bn
- KR₩126bn
- KR₩76bn
Annual balance sheet for BCWorldPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4,503 | 8,058 | 11,166 | 7,911 | 6,811 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 15,942 | 17,778 | 19,483 | 20,914 | 20,292 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 37,235 | 43,609 | 48,086 | 44,558 | 49,075 |
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 132,370 | 130,119 | 125,628 | 120,985 | 117,852 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 179,358 | 183,051 | 184,111 | 176,313 | 176,801 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 55,892 | 84,206 | 92,246 | 85,865 | 89,713 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 97,901 | 103,499 | 102,468 | 99,645 | 105,521 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 81,458 | 79,552 | 81,643 | 76,668 | 71,281 |
| Total Liabilities & Shareholders' Equity | 179,358 | 183,051 | 184,111 | 176,313 | 176,801 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |